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Abstract: The genetic modification of human T lymphocytes with established non-viral methods is
inefficient. Linear polyethylenimine (l-PEI), one of the most popular non-viral transfection agents for
mammalian cells in general, only achieves transfection rates in the single digit percentage range for
these cells. Here, a well-defined 24-armed poly(2-dimethylamino) ethyl methacrylate (PDMAEMA)
nanostar (number average of the molecular weight: 755 kDa, polydispersity: <1.21) synthesized
via atom transfer radical polymerization (ATRP) from a silsesquioxane initiator core is proposed as
alternative. The agent is used to prepare polyplexes with plasmid DNA (pDNA). Under optimal
conditions these polyplexes reproducibly transfect >80% of the cells from a human T-cell leukemia
cell line (Jurkat cells) at viabilities close to 90%. The agent also promotes pDNA uptake when simply
added to a mixture of cells and pDNA. This constitutes a particular promising approach for efficient
transient transfection at large scale. Finally, preliminary experiments were carried out with primary
T cells from two different donors. Results were again significantly better than for l-PEI, although
further research into the response of individual T cells to the transfection agent will be necessary,
before either method can be used to routinely transfect primary T lymphocytes.
Keywords: non-viral gene delivery; Jurkat cells; human T lymphocytes; primary cells;
poly(2-dimethylamino) ethyl methacrylate; polycation; nanostar
1. Introduction
Genetically engineered primary human T lymphocytes (T cells) have their place in basic research
and increasingly also in medical therapy [1]. A pertinent example is the generation of chimeric
antigen receptor (CAR) T cells as basis for an FDA-approved adoptive cell therapy (ACT) to treat
acute lymphoblastic leukemia (ALL) [2,3]. Primary T cells are isolated from the patient’s blood and
are genetically modified to recognize the cancer cells. The T cells are then expanded and given back
to the patient. In this case, the cells are permanently transfected, i.e., the recombinant DNA is stably
integrated into the genome and passed on to the daughter cells during cell division (expansion).
Alternatively, it has been proposed to first expand the T cells and then transfect them transiently. In this
case, the DNA remains episomal, gene expression is transitory and will cease as the DNA is diluted
during further cell division. Although not yet accepted by the regulatory authorities, transiently
transfected cells are thought to show less cross reactivity and be less of a burden on the patient [4].
In nearly all cases of efficient T cell transfection discussed in the literature, viruses were used to
transduce the cells. Although very efficient, viruses have some drawbacks, mostly related to their
immunogenicity and a limitation in the amount of DNA to be transferred. Physical methods, such as
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electroporation, have been suggested as alternative [5]. However, electroporation requires prohibitory
large numbers of cells, since survival is low, while important cellular functions may be perturbed [6,7].
Chemical transfection methods, such as lipofection or polyfection, which are standard alternatives
for many mammalian cells, are less popular in the case of T cells, due to an extremely low efficiency.
T cells have for instance, shown resistance to common lipofection reagents [8]. Gene transfer using
polycations is also more difficult in the case of T cells. Several groups including our own have, e.g.,
shown that polyethylenimine (PEI), the current “gold standard” in non-viral chemical transfection
using polycations, only reaches transfection efficiencies in the single digit range, which is much too
low for most applications [9–11]. The reason for this inefficiency is not quite clear. However, in vitro
transfection begins with an interaction of the polyplexes with the cellular membrane. It is thought that
in the case of PEI, this interaction takes place primarily with negatively charged membrane proteins,
such as sulfated proteoglycans [12–15]. Some studies with PEI indicate that these interactions are also
decisive for polyplex internalization [16,17]. T cells and in particular some of their subpopulations,
are known to have unusually high or low proteoglycan contents in their cellular membranes [18].
The same is true for the Jurkat cells [19], i.e., cells from a human leukemia cell line, which are commonly
used as model cells for the T cells. A low proteoglycans content may therefore be partly responsible
for a resistance to PEI as a transfection agent.
In the past, we have proposed poly-2-(dimethylamino)ethyl methacrylate (PDMAEMA) as
an efficient transfection agent in a wide range of cell lines including some that are hardly
transfectable with PEI [11] which have led us to speculate about a different uptake mechanism [20].
Well-defined, multi-armed nanostars based on the polycation poly-2-(dimethylamino)ethyl
methacrylate (PDMAEMA) outperformed linear PEI (l-PEI) for the transfection of Jurkat cells. However,
elevated transfection efficiencies (up to 50%) were linked to a low viability (≤40%) in these cases [11].
In the previous experiments, the PDMAEMA nanostars had been used in a manner similar to that
proposed for PEI in standard transfection protocols. The plasmid DNA (pDNA) and a defined surplus
of the polycation were mixed and incubated for polyplex formation. Afterwards, the polyplexes
were added to the cells under static conditions (cells settled at the bottom of a Petri dish or well
plate). After another incubation step, the cells were separated from the transfection cocktail through
centrifugation and placed into fresh culture medium for recovery.
Debatably, electroporation and, in particular, nucleofection [21] are at present the most efficient
non-viral methods for the genetic modification of T cells. Both call for the pre-mixing of the cells
and the pDNA at high cell density (between 1 × 107 cells mL−1 and 8 × 107 cells mL−1) prior to
the high voltage treatment [22]. Taking this into consideration, we argue that the chemical high cell
density (HCD) transfection protocol developed 14 years ago by the group of Florian Wurm [23–25] for
production cell lines like Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293)
cells, might also be suitable to transiently deliver pDNA into T cells, even though to the best of our
knowledge it has never been tried for this purpose before. For HCD transfection, the pDNA is directly
mixed into a highly concentrated cell suspension (≥2 × 107 cells mL−1), followed by the addition
of a polycation (PEI in most previous experiments), a short incubation and then a dilution of the
transfection cocktail by at least an order of magnitude. The transfection agent is thus not removed, but
simply diluted in this approach.
The present study summarizes the systematic optimization of nanostar-based transfection
strategies for genetic engineering of human T cell, both at the research and at the therapeutic scale.
Jurkat cells were used as model cells for human primary T cells in the development of the procedures,
which were then applied in a preliminary proof-of-concept study to human primary T lymphocytes
from two different donors.
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2. Materials and Methods
2.1. Materials
If not otherwise indicated, we used Greiner bio-one (Greiner Bio-One International GmbH,
Frickenhausen, Germany) as supplier for cell culture materials and Sigma-Aldrich for chemicals
(Sigma-Aldrich, Taufkirchen, Germany). Linear PEI (l-PEI, 25 kDa) was from Polysciences (Polysciences
Europe GmbH, Eppelheim, Germany). Trypan blue solution (0.4%) was from VWR (VWR International,
Ismaning, Germany). Recombinant human interleukin 2 (rhIL-2) was from BD Biosciences (Becton
Dickinson, Heidelberg, Germany). Fetal calf serum (FCS), L-glutamine, penicillin, and streptomycin
were from Biochrom (Biochrom AG, Berlin, Germany). Dulbecco’s Phosphate-Buffered Saline without
Ca2+ and Mg2+ (DPBS) was from Lonza (Lonza Group AG, Visp, Switzerland). Hepes-buffered glucose
solution (HBG, 20 mM Hepes, 5 wt% glucose, pH 5.5) was prepared in house and sterilized by filtration
(0.2 µm Minisart, regenerated Cellulose, Sartorius, Göttingen, Germany). Cell culture media R10 (Roswell
Park Memorial Institute (RPMI) 1640 without glutamine, add 10 vol% fetal calf serum, 2 mM L-glutamine,
100 IU mL−1 penicillin and 100 µg mL−1 streptomycin) and Opti-MEM were from Biochrom AG (Berlin,
Germany) and Thermo Fisher Scientific (Dreieich, Germany), respectively. LymphoGrow medium (LG,
containing 2 mM L-glutamine and undisclosed amounts of antibiotics) was from Cytogen (Cytogen
GmbH, Sinn, Germany). LG stimulates the growth of peripheral blood lymphocytes and contains also
proprietary amounts of pre-tested fetal bovine serum (FBS) and phytohemaglutinin (PHA-P,≤10 µg mL−1
mitogenic activity). For pre-equilibration, media were incubated for at least 1 h in a standard mammalian
cell culture incubator (37 ◦C, 5% CO2, 95% humidity, Steri-Cult, Thermo Forma, Fisher Scientific GmbH,
Schwerte, Germany). Blood was obtained from the Bavarian Red Cross.
2.2. Cells and Maintenance
The Jurkat cells (TIB-152, American Type Culture Collection (ATCC), human leukemia T cells,
suspension cells) were maintained in R10, as recommended by the supplier; a seeding density of
1 × 105 cells mL−1 was used during passaging and the maximal cell density was never allowed to
exceed 3 × 106 cells mL−1. Cells were cultivated at 37 ◦C in humidified 5% CO2 atmosphere.
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy donors by
Ficoll gradient centrifugation with a lymphocyte separation medium (LSM1077, PAA Laboratories,
Pasching, Austria) according to the supplier’s instructions. The freshly isolated PBMCs were seeded at
2.5 × 106 cells mL−1 in Lymphogrow (LG) medium in 75 cm2 T-flasks. After 24 h cultivation, the cell
suspension was transferred to a new flask, to separate the PBMCs from adherent growing immune
cells. PBMCs were cultivated for a further 24 h before transfection.
2.3. Plasmid
pEGFP-N1 (4.7 kb) encoding for the enhanced green fluorescent protein (EGFP) driven by the
cytomegalovirus (CMV) immediate early promoter was from Clontech Laboratories, Inc. (Mountain
View, CA, USA). The plasmid was amplified in E. coli (LB medium) using standard laboratory
techniques. The EndoFree Plasmid Kit (Giga Prep/Maxi Prep) from QIAGEN (QIAGEN GmbH,
Hilden, Germany) was used for purification (quality control: >80% supercoiled topology (agarose
gel; 1% TAE) and A260/A280 ≥1.8). Purified plasmids were solubilized (1.7 mg mL−1) in sterile
ultrapure-water (Sigma-Aldrich, Taufkirchen, Germany).
2.4. Transfection Agent
The transfection agent was a well-defined 24-armed PDMAEMA nanostar (number average of
the molecular weight: 755 kDa, polydispersity: <1.21) synthesized as previously described [26] via
atom transfer radical polymerization (ATRP) from a silsesquioxane initiator core. Each arm of the
nanostar contained an average of 200 monomeric units, Scheme 1. A stock solution (1.82 mg mL−1)
was prepared in sterile ultrapure PCR-water (Sigma-Aldrich).
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2.5. Transfection of Jurkat Cells Using Polyplexes (6- ell Plate, Eppendorf Tube Formats)
According to the standard prot col, cel s ested by centrifugation (200 g, 5 min) 24 h
before transfection and seed d at 0.05 or 0.1 × 106 1 (l ving cell density) in fresh medium, as
indicated. On the day of transfection, the cells (ex e tial growth phase, viability >90%) were again
harvested by centrifugation, washed twice with DPBS and seeded at a density of 0.2 × 106 cells mL−1
(living cell density) in 6-well or 2 mL Eppendorf tubes (1 mL of pre-equilibrated culture medium).
The well plates were put back into the incubator for one hour. The Eppendorf tubes were stored on ice
to reduce the metabolic activity of cells during the 1 h incubation.
In the meantime, polyplexes were prepared in a final volume of 50 (transfection in Eppendorf
tubes) or 200 µL (transfection in 6-well plates) by first diluting the necessary volume of the pDNA stock
solution in Hepes-buff red glucose s lution (HBG), followed by the ad tion of sufficient amounts
(in a single drop) f the polymer stock solution to achieve the indicated N/P ratio (ratio of poly er N
to DNA P). The mixture was vortexed for 10 s and incubated for 20 min at room temperature (polyplex
formation). Then, the indicated amount of Opti-MEM (1 mL for the 6-well plates, 0.15 mL or 0.45 mL
for the Eppendorf tubes) was added, followed by vortexing and another 10 min incubation at room
temperature. In case of a transfection in 6-well plates, the polyplex mixture was added drop-wise to the
1 mL of cell suspension in the wells and distributed by gentle rocking. After an incubation period of up
to 4 h in the cell culture incubator, the supernatant was removed and replaced by 2 mL of fresh growth
medium. In case of the transfections in the Eppendorf tubes, the cells were recovered by centrifugation
(200 g, 5 min) and the supernatant was discarded. The cell pellet was dis ocated by scratching prior
to adding the polyplex/Opti-MEM mixture. Cells and polyplexes were gently mixed before th tube
was placed upright in the cell culture incubator. After the indicated time span of incubation (15 min,
30 min, 90 min, 120 min, or 240 min), the cells were again recovered by centrifugation, the supernatant
was discarded and the cell pellet was re-suspended in 2 mL R10 and transferred to a 6-well plate.
Cells from all experiments were analyzed for viability (counterstaining with propidium iodide, PI)
and transfection efficiency (% of green fluorescent protein (GFP) -positive cells) by flow cytometry 48 h
post transfection.
2.6. High Cell Density Protocol for Transfection of Jurkat Cells
The high cell densi y (HCD) transfection protocol used here was based on a protocol originally
proposed by Durocher et al. for HEK293 cells [27]. Briefly, cells were harv sted by centrifugation
(200 g, 5 min) 24 h prior to transfection nd seeded at 1.0 × 106 cells mL−1 (living cell density) in
fresh culture medium. On the day of transfection, the cells (exponential growth, >90% viability)
were again harvested by centrifugation, washed twice with DPBS and re-suspended at a density of
2 × 107 cells mL−1 (living cell density) in a suitable amount of pre-equilibrated Opti-MEM. The cell
suspension was then transferred into 2 mL Eppendorf tubes (0.25 mL, total: 5 × 106 cells) or 50 mL
Falcon tubes (5 mL, total: 1 × 108 cells). The indicated amount of pDNA was added and the tubes
were inverted several times for mixing. Then, a defined amount of the transfection agent was added
to achieve the indicated N/P ratio and mixed in. The tubes were then fixed on a SB2 rotator unit
(Stuart, Barloworld Scientific, Burlington, NJ, USA) placed in a 37 ◦C room and rotated at 20 rpm for
4 h. At the end of the incubation time, the cells were diluted (dilution factor: 20, unless indicated
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otherwise) in R10 and the suspensions transferred to either a 10 cm tissue culture dish (Eppendorf
tube) or a 100 mL spinner flask (Falcon tube). For further scale up, 2 × 109 cells were transferred into
two 50 mL Falcon tubes (25 mL each, 4× 107 cells mL−1), pDNA and polymer were added sequentially
as described above. Thereafter, the mixtures were immediately combined in a 100 mL spinner flask
and placed for incubation in the cell culture incubator for 4 h (70 rpm, CELLSPIN stirrer, INTEGRA
Biosciences AG, Biebertal, Germany). At the end of that time, the cells were diluted in R10 (dilution
factor: 20) and transferred to a 1 L spinner flask for further cultivation of the cells. Cells from all
experiments were again analyzed for viability (PI) and transfection efficiency (EGFP) by flow cytometry
48 h post transfection.
2.7. Transfection of Primary T Cells
After two days of cultivation of the PBMCs in LG medium, mainly CD3+ cells with blasted
morphology (“activated T cells”) were obtained as determined by flow cytometry. Transfections were
performed in Opti-MEM using polyplexes and HCD protocols both in Eppendorf tube format as
described above, excluding the cell seeding step 24 h before transfection. For the polyplexes-based
transfection (0.2 × 106 cells, N/P 10, transfection volume 0.5 mL), two batches of polyplexes were
prepared in parallel (experimental replicates) but added sequentially to the cells implicating that for
the second replicate, polyplexes incubation at room temperature and storage of the cells on ice was
somewhat longer (15 min to 20 min). After 90 min incubation with the polyplexes, the cells were
recovered by centrifugation, the supernatant was discarded and the cell pellet was re-suspended
in 2 mL LG medium supplemented with 11 ng mL−1 rhIL-2 to improve T cells proliferation [28]
and transferred into 6-well plates. For HCD transfection, 5 × 106 cells were incubated with 3 µg
polymer per 106 cells for 4 h (N/P 10, 0.25 mL). Thereafter, the cells were diluted (dilution factor: 80)
in LG medium supplemented with 11 ng mL−1 rhIL-2 and the suspension transferred into a 10 cm
tissue culture dish. Cells from all experiments were again analyzed for viability (PI) and transfection
efficiency (EGFP) by flow cytometry 48 h post transfection.
2.8. Analytics
Jurkat cell numbers and viabilities during passaging and seeding steps were evaluated by trypan
blue exclusion assay with a hemocytometer (Neubauer Improved, VWR International, Ismaning,
Germany). Cell number and viability of primary T cells were evaluated using the automated
fluorescence cell counter Luna (Logos Biosystems, Gyeonggi-do, Korea). A 2 µL sample of cell
culture was mixed with 18 µL Staining-Mix (Acridin Orange and Propidium iodide, proprietary
concentrations, Logos Biosystems) and loaded into the chamber of a PhotonSlide (Logos Biosystems).
Afterwards, the slide was inserted into the slide port of the counter and the cells were counted. If the
cell concentration was above 5 × 106 cells mL−1 the sample was diluted with DPBS (10-fold).
Zeta potentials and hydrodynamic radii of the polyplexes were determined using a Zetasizer Nano
ZS (Malvern Instruments, Herrenberg, Germany). For zeta potential measurements polyplexes were
produced in 200 µL HBG using 15 µg of pDNA and varying amounts of the nanostar stock solution to
reach the indicated N/P ratio. Mixtures were vortexed for 10 s and incubated at room temperature
for polyplex formation and maturation. After 20 min of incubation, the preparation was diluted with
1 mL Opti-MEM. The size of the polyplexes was determined by noninvasive back scattering in the
same instrument utilizing a He–Ne laser (λ = 633 nm, max power = 5 mW). Hydrodynamic radii
were followed for 20 min in HBG. Then, polyplexes were diluted 6-fold with Opti-MEM and further
monitored. All incubations and measurements were performed at room temperature.
For the gel retardation assay, polyplexes were produced in 200 µL HBG using 15 µg of pDNA
and varying amounts of the nanostar stock solution to reach the indicated N/P ratio. Mixtures
were vortexed for 10 s and incubated at room temperature for polyplex formation and maturation.
After 20 min of incubation, 20 µL 6X loading buffer (60% glycerol—10 mM Tris-HCl pH 7.6—60 mM
EDTA—0.03% bromophenol blue) were added and 15 µL of these mixtures were analyzed in 1%
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(w/v) agarose gels with Tris-acetate-EDTA as running buffer (running time 90 min, applied voltage
90 V). Gels were stained with ethidium bromide (EtBr, 10 µg mL−1) and the DNA visualized under
ultraviolet (UV) light (254 nm).
For phenotyping of the primary T lymphocytes, cell surface markers CD3 and CD25 were assessed
by staining the cells with specific antibodies (mouse-anti human CD3-PE # 555340, mouse-anti human
CD25-PE-Cy5, # 555433; both from BD Bioscience, Becton Dickinson, Heidelberg, Germany) according
to the manufacturer’s instructions and analyzed by flow cytometry.
For flow cytometry (Cytomics FC500 equipped with a 488 nm argon-ion laser, Beckman Coulter,
Krefeld, Germany), cells were recovered by centrifugation (200 g, 5 min) and re-suspended in 500 µL
DPBS containing PI (1 µg mL−1). Forward scatter (FSC), side scatter (SSC), green fluorescence (EGFP,
em 510 nm), and red fluorescence (PI, em 620 nm; PE, em 575 nm; PE-Cy5, em 655 nm) were recorded.
Scatter properties (FSC/SSC) were used to select a region representing single, non-apoptotic cells,
while disregarding dead cells, debris, and cellular aggregates. Cells “transfected” at N/P = 0, i.e., in
the absence of the transfection agent, were used to set the measurement parameters. Histogram plots
of the respective fluorescence intensities (log scale) were used to estimate the percentage of transfected
cells and the expression level distribution according to: low producers (L): fluorescence intensity
between 1 a u and 10 a u.; middle producers (M): fluorescence intensity between 10 a u and 100 a u.;
high producers (H): fluorescence intensity >100 a u., in the non-apoptotic cell population. Dead cells,
counterstained by PI, were evaluated in the total measured cell population. Flow cytometry data were
evaluated using FlowJo software v 10.5.0 (Tree Star, Stanford University, Stanford, CA, USA, 2016).
2.9. Statistical Analyses
Group data are reported as mean ± standard deviation (SD). If not otherwise stated, n represents
the number of independent experiments. Sigma Plot software (version 11.0, Systat software Inc.,
San Jose, CA, USA, 2008) was used for One-way ANOVA with Bonferoni multiple comparisons tests
to determine whether data groups differed significantly from each other. Statistical significance was
defined as p < 0.05.
3. Results and Discussion
3.1. Physicochemical Characterization of the Polyplexes
In the standard transfection protocol, polyplexes are initially formed between the pDNA and
a surplus of the polycationic transfection agent, which are then added to the cells. A surplus of
transfection agent is required to overcompensate the negative charge of the pDNA and give the
polyplexes the positive net-charge required for attractive electrostatic interaction with the cellular
membrane. In addition, the size (hydrodynamic radius) of the polyplexes should ideally range between
50 nm and 200 nm [29].
The zeta potential was measured for the polyplexes as a function of the N/P ratio (ratio of
polymer N to DNA P), Table 1. Hepes-buffered glucose solution (HBG) was used as matrix for
polyplex formation, because in our hands, this buffer originally proposed by Van Gaal et al. [30] had
previously been more efficient in transfecting mammalian cells that the commonly used unbuffered
150 mM NaCl [31].
Table 1. Zeta potentials of polyplexes at the indicated N/P-ratios.
N/P Ratio Zeta Potential Values (mV)
3 −30.7 ± 2.1
5 −0.4 ± 4.0
10 7.4 ± 1.8
20 10.1 ± 1.2
The zeta potential of the non-complexed DNA is −26.9 ± 3.2 mV. Shown are mean values ± standard deviation
(SD), n = 3.
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As expected, the zeta potential of the polyplexes increases with increasing N/P ratio. An N/P
ratio of at least 5 is required for a full charge compensation of the DNA. When the N/P ratio is
increased further, the zeta potential reaches a final value of +10 mV. As shown as example for N/P 20
in Figure 1, the hydrodynamic radius of the polyplexes changed little with incubation time. Moreover,
with a value of 70.4± 4.5 nm the polyplexes should be well suited to transfect mammalian cells. This is
different from the results shown for l-PEI polyplexes in HBG which initially was much smaller 33 nm
and then increase to 130 nm after dilution [20].
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transfection results, the cells should be rapidly dividing and in the exponential phase of growth.
To assure this, standard transfection protocols call for passaging of the cells into fresh medium 24 h
prior to transfection. For Jurkat cells, a seeding density of 0.1 × 106 cells mL−1 is recommended
by the supplier (ATCC). Transfection efficiencies improved, however, by 1.8-fold (~17% to ~30%),
when the cells were instead seeded at 0.05 × 106 cells mL−1 and transfected 12 h afterwards.
Low seeding cell densities in this range are, incidentally, also recommended in nucleofection protocols
for T lymphocytes.
Under these conditions, the nanostar was more efficient in transfecting the Jurkat cells than l-PEI,
but also significantly more toxic, Table 2. The different N/P ratios (20 for l-PEI, 10 for the nanostar)
used in these experiments were chosen because they had previously been identified to be the most
suitable for Jurkat cells in experiments involving a variant of the nanostar with 20 arms and l-PEI as
reference material [11].
Table 2. Transfection of Jurkat cells from exponentially growing cultures using nanostars in comparison
to l-PEI (PEI: polyethylenimine).
Viability (%) Transfection Efficiency (%)
Total Low Producers Middle Producers High Producers
PEI 83.1 ± 3.8 7.9 ± 0.7 2.6 ± 0.1 2.4 ± 0.1 2.9 ± 0.6
Nanostar 31.3 ± 11.2 57.7 ± 8.9 24.6 ± 7.8 17.3 ± 2.1 15.9 ± 1.0
Transfection volume 2.2 mL. l-PEI: 5 µg polymer, 1.9 µg pDNA, N/P 20; nanostar: 10 µg polymer, 2.1 µg pDNA,
N/P 10. Shown are mean values ± SD, n ≥ 2.
In term of transfection efficiency, the results obtained here for the nanostars are better than
the ones previously determined for nanostars of similar chemistry, [11] including some micellar
constructs [31,32], while viabilities were lower. The l-PEI results are in the expected single digit range.
l-PEI was chosen because in the past it showed in our hands less cytotoxicity at equal transfection
efficiency in various cell lines. However, similar low transfection efficiency in Jurkat cells has been
reported for bPEI [9].
The typical correlation between the efficiency and the toxicity of a non-viral transfection
agent [33,34] is therefore also found in our case. It is generally considered difficult to uncouple
the two effects. However, in a recent paper [31], we have shown that independent of the N/P ratio the
cytotoxicity of the transfection cocktail depends strongly on the absolute amount of polymer added.
This phenomenon has been obscured in most previous investigations by the fact that the N/P ratio is
adjusted by keeping the pDNA amount constant while increasing that of the polycation.
Polymer concentrations and N/P ratios in the standard protocol used here had been established
and used with success for various mammalian cells [11]. However, in view of the low viability, Jurkat
cells were subsequently transfected keeping a N/P ratio of 10 constant, but reducing the amount
of added polyplex and thus the amount of polymer per cell (“polymer density”), Figure 3. Starting
conditions in Figure 3, i.e., 2.1 µg pDNA per well and a polymer density of 50 µg per 106 cells
correspond to the values in the standard protocol.
Transfection efficiency and viability show differences in their dependency on the polymer density.
An optimum with >40% viable cells and a transfection efficiency of approximately 60% is reached
at N/P 10 for a polymer density of 20 µg per 106 cells. Any further reduction of the polymer
density (at N/P 10) would increase viability at the price of significantly reducing the transfection
efficiency. Reduction of the polymer density (per cell) is linked with a dilution of the polyplexes in the
transfection volume. We can speculate that, less polyplexes (i.e., lower concentration) will lower their
frequency of contact with the surface of cells, and thus their transfection effectiveness under normal
gravitational conditions. Therefore, it was next tested whether a reduction of the transfection volume
(i.e., an increase in cells and polyplexes concentration) under otherwise identical conditions would
improve the transfection efficiency while keeping the cytotoxicity unaffected.
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The total amount of cells in all experiments was kept constant and the transfection volume was
reduced (1.2 mL for 6-well plate). Polymer densities of 25 µg per 106, 15 µg per 106, and 10 µg per
106 cells were chosen to cover the range of interest, Table 3.Processes 2018, 6, x FOR PEER REVIEW  9 of 17 
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Figure 3. Influence of the “polymer density” (amount of nanostar ad ed per 106 cells) on transfection
efficiency and viability keeping the N/P ratio constant at a value of 10. (Total cells: 0.2 × 106,
transfection volume 2.2 mL (0.2 mL polyplex solution), bars represent percentages of transfected cells
within the viable cell population (white: low producer, grey: middle producer, black: high producer),
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Table 3. Comparison of the transfections in 6-well plates for increasing cell and polymer concentrations
at constant cell number.
Polymer Density
(µg per 106 Cells)
Polymer Concentration
(µg mL−1) Viability (%) Transfection Efficiency (%)
25 4.0 39.1 ± 1.9 . 0.3
15 2.4 80.4 39.4
10 1.6 94.8 ± 0.8 8.9 ± 5.7
0.2 × 106 cells per sample, N/P 10. Shown are mean values ± SD, n ≥ 2 except for 15 µg polymer, where n = 1 in
that case data represent the averaged values of one experiment carried out in duplicate.
Transfection efficiencies and viabilities obtained in these experiments were similar as before.
This indicates that increasing the concentration of the polyplexes 2-fold does not influence the
transfection results and that it is indeed the polymer density which determined the outcome of
the transfection. In consequence, the optimum result shown in Figure 3, i.e., a transfection efficiency of
60% at 42% viability, seems to be the best result an adaptation of the standard transfection protocol can
give in the case of Jurkat cells. While considerably better, than anything l-PEI can produce, the low
viability in particular is a concern, since any attempt to improve this value must be expected to
dramatically reduce the transfection efficiency. For comparison, the Nucleofection technology has been
reported to reach transfection efficiencies of >85% at 90% viability [35].
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3.3. High Cell Density Transfection of Jurkat Cells
The high cell density (HCD) protocol developed here for the transfection of Jurkat cells was based
on a protocol originally developed for CHO and HEK293 cells [25]. One major difference for HCD
protocol is that a high density cell suspension and the pDNA are premixed and then the polycation
is added. In a first condition screening experiment, the cells were transfected in Eppendorf tubes
at a density of 20 × 106 cells mL−1 in Opti-MEM varying again the absolute amount of pDNA and
polymer added, while keeping an N/P ratio of 10, Figure 4. The transfections were performed at 37 ◦C
under constant agitation (cell rotator, 20 rpm). After 4 h of incubation, the cell density was adjusted to
1 × 106 cells mL−1 by dilution R10.
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Figure 4. Optimization of the polymer density in high cel density (HCD) transfections of Jurkat cel s.
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An N/P of 10 was adjusted in all experiments.).
Two things are re arkable about these results. Firstly, much lower polymer densities suffice
for maximum transfection in the HDC protocol, where the highest transfection efficiency (45 ) was
observed when using 4 µg of polymer per 106 cells. This suggests, as postulated before for the 6-well
transfection, that the “molecular spacing”, i.e., the likelihood of a contact between cells and poly ers,
influences the outcome of the transfection. Secondly, these high transfection rates are apparently still
compatible with good viability (>75% for 4 µg of polymer per 106 cells). Incidentally, when l-PEI was
tested in the HCD transfection protocol, transfection efficiencies below 5% were obtained. l-PEI was
therefore not tested any further.
In general, the viability showed the expected dependency on the polymer density. However, due
to the higher cell numbers (20 × 106 cells mL−1 in the HCD protocol, 0.09 × 106 cells mL−1 in the
standard protocol), higher polymer concentrations are needed to achieve a certain polymer density
in the HCD protocol, which in turn has an effect on the viability. For example, 10 µg of polymer per
106 cells still leaves over 90 of the cells viable in the standard protocol, Figure 3, while 9 µg per
106 cells reduced the viability of the cells to less than 40% in the HCD protocol, Figure 4. The fact that
the polymer is added as a free agent in the HCD protocol, whereas polyplexes are used in the standard
protocol, may also increase the cytotoxic effect of the transfection agent.
According to the supplier of the cells (ATCC), Jurkat cells are sensitive towards high cell densities
and should in principle be maintained between 1 × 105 viable cells mL−1 and 1 × 106 viable
cells mL−1 throughout. In an atte pt to further i prove the transfection efficiency, the dilution factor
post-transfection was increase to 80 to achieve a density of 0.25 × 106 cells mL−1 at the beginning of
the cultivation. In addition, the /P ratio was varied (7.5, 10, 15) for polymer densities of 2 µg per
106 cells, 3 µg per 106 cells, and 4 µg per 106 cells, Figure 5.
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The transfection efficiencies measured 48 h post-transfe tion showed no statisti ally rel vant
vari tion in these experiments (p < 0.05), while they were higher than the ones in Fig re 4.
This might eventually be ascribed to a better fitness of the cells du to the lower seeding cell density
post-transfection. The distribution over low, middle, and high producers is also similar. Cell viabilities
were generally high (≥60%). Again, observable diff rences were ot statistically relevant.
The scale of th HCD pr tocol was subsequently increased to 108 cells (Falcon tube, 5 mL
transfec ion volume) as well as to 2 × 109 cells (Falcon tubes, 2 × 25 mL), all the time adjusting
a polymer density of 3 µg polymer per 106 cells. To accommodate the largest transfection volume
(50 mL), only the addition of the polymer to the DNA/cell mix ure took place in Falcon tubes (assumed
to allow more rapid mixing), while the subsequent incubation was already performed in a 100 mL
spinner flask stirred continuously at 70 rpm. Only a N/P of 10 was investigated for the largest scale.
Results are summarized in Table 4.
Table 4. Large scale high cell density (HCD) transfection of Jurkat cells.






1 × 108 7.5 83.5 67.2 ± 13.9 52.7 ± 0.7 21.2 ± 3.9 20.0 ± 2.2 11.5 ± 6.9
10 62.6 72.9 ± 9.4 58.2 ± 10.9 27.6 ± 7.3 21.3 ± 4.8 9.3 ± 3.0
15 41.8 68.8 ± 20.3 50.6 ± 7.0 25.8 ± 13.9 16.9 ± 1.3 7.9 ± 5.6
2 × 109 10 1252 58.2 ± 2.1 70.0 ± 1.9 38.4 ± 0.6 23.7 ± 1.2 7.9 ± 0.5
1× 108 cells, transfection volume 5 mL, 50 mL Falcon tubes. 2× 109 cells, transfection volume 50 mL, 100 mL spinner
flask. Polymer density: 3 µg per 106 cells. Polymer concentration: 60 µg mL−1. Dilution factor post-transfection: 20.
Amount of pDNA is given as per sample. Shown are mean values ± SD, n ≥ 2.
Transfection efficiencies and viabilities obtained at larger scale were similar to those obtained
in the corresponding small-scale experiments, Figure 5, but higher than the ones obtained during
the conditions screening experiment Figure 4. Throughout, approximately 70% of the cells remained
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viable, out of which 70% were also transfected. The distribution over low, middle, and high producers
was also similar to that of the small-scale experiments. An HCD transfection of Jurkat cells can thus
be used to efficiently transfect at least up to 2 × 109 Jurkat cells at a time with tolerable mortality
and should easily be scalable beyond this point by keeping the polymer density at 3 µg per 106 cells.
This approach may hence be convenient in the context of T cells therapy, where large number of cells
need to be transiently transfected.
3.4. Adaptation of the Standard Protocol to Eppendorf Tubes
Finally, the standard protocol, originally developed for a plate-based geometry, was adapted to the
Eppendorf tube format. In this case, the harvested cells (stored on ice) were directly suspended in the
polyplex-in-medium suspension (0.25 mL). As a result, the polymer concentration during transfection
is 4.8-fold to 8.8-fold higher in the tubes than in the plates with 1.2 mL and 2.2 mL transfection volumes,
respectively. Polymer densities of 50 µg per 106 cells, 25 µg per 106 cells, 15 µg per 106 cells, and 10 µg
per 106 cells were adjusted in these experiments to cover the range of interest. The N/P ratio was
again set to 10.
When the standard incubation time of 4 h was chosen, cells did not survive. When the incubation
time with the polyplexes was lowered to 2 h, better results were obtained, Table 5. Moreover, in all
cases, a polymer density of 50 µg polymer/106 cells was too toxic for the cells.
Table 5. Transfection in Eppendorf tubes as a function of the polymer density.
Polymer Density
(µg per 106 Cells)
Polymer Concentration
(µg mL−1) Viability (%) Transfection Efficiency (%)
25 20 11.0 ± 9.7 64.5 ± 2.1
15 12 6.1 74.4
10 8 17.0 ± 5.5 65.4 ± 14.0
0.2 × 106 cells per sample; N/P 10; incubation with polyplexes 2 h. Shown are mean values ± SD, n ≥ 2 except for
15 µg polymer, where n = 1 (data represent the averaged values of one experiment carried out in duplicate).
Compared to the results for the 6-well plates (Figure 3), higher transfection efficiencies were
reached, but viabilities were low. This supports our assumption that the molecular spacing during the
transfection is a relevant parameter to consider. Doubling the transfection volume to 0.5 mL, while
keeping the polymer density constant (15 µg per 106 cells), led to an increase in viability by a factor
of 7.4 (45.1%) while the transfection efficiency increased to 90.9% (12% low producer, 45% middle
producer, 34% high producer), arguing that the polymer concentration, which had served well in the
6 well plate format, was too high in case of the Eppendorf tube format. Indeed, when the polymer
density was lowered to values more typical of the HCD transfection protocol (see above), viabilities
and transfection efficiencies improved, in particular, when the incubation time was further reduced
(90 min, 30 min, 15 min), Figure 6.
At incubation times of 30 and in particular 90 min (Figure 6A,B), low polymer densities of 5 and
4 µg per 106 of cells resulted in excellent transfection efficiencies of ≥80% at viabilities of more than
80%. However, an incubation time of only 15 min was obviously too short to achieve transfection,
Figure 6C. The cytotoxic response, on the other hand, is very fast and can be already be detected within
the first 15 min of incubation and might be due to plasma membrane permeabilization. Moreover,
in comparison to the experiments in 6-well plates, the level of transgene expression was shifted
towards middle and high producers, when the cells were transfected in Eppendorf tubes. Interestingly,
the transfection efficiency but not the viability seemed to pass through a minimum in these experiments.
Low polymer densities thus achieve good transfection efficiency, while being gentle on the cells.
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In the Eppendorf tube protocol, cells and polyplexes are used at higher concentrations than in the
standard 6-well format. For polymer concentrations ≤2.4 µg mL−1, this does not extensively influence
the viability (60%) but dramatically improves the transfection efficiency (compare Figures 3 and 6A).
Moreover, cells are directly suspended in the polyplex preparation in the Eppendorf protocol and thus
will settle together in response to gravity at the bottom of the tube during incubation. Creating a high
local polyplex concentration presumably enforces interactions between cells and polyplexes. It has,
e.g., been known for some time, that the transfection efficiency can be increased using centrifugal forces
to promote sedimentation of small polyplexes over adherent cells [36]. The result is an intensification
of the contact frequency and a reduction of mass transfer limitations. Both lead to an acceleration of
the transfection kinetics, which in turn allows a reduction of the incubation time. Since DNA uptake
and cytotoxic effects are both time dependent, this creates a situation where a significant number of
cells take up sufficient amounts of DNA to allow transgene expression 48 h later, while surviving the
procedure in large numbers. Thus, for the first time, it is possible to chemically transfect Jurkat cells
with both a transfection efficiency and a viability above 80%. Such results have only been obtained
so far with nucleofection kits [35], which are associated with high costs and might not be suitable for
large-scale experiments.
The level of transgene expression is also improved in the Eppendorf tube protocol. Improved
transgene expression can, e.g., be the results of an improved cellular uptake (i.e., more DNA
molecules enter the cells), an improved nuclear uptake (i.e., more DNA molecules enter the nucleus),
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or improved transcription (i.e., the transcriptional activity of the CMV promoter is upregulated).
The cellular uptake can be enhanced due to the increased frequency of contact between cells and
polyplexes as postulated above and might in turn lead to higher amounts of pDNA in the nucleus.
The transcriptional activity of the CMV promoter used here to drive EGFP expression is sensitive
to a variety of environmental stresses (e.g., osmotic shock, oxidative stress) and can be upregulated
via an intracellular stress-activated Mitogen-Activated Protein (MAP) kinase pathway [37]. In the
past, PEI-based polyplexes have been shown to induce the generation of reactive oxygen species
(ROS) [38,39]. A similar effect by the polyplexes used in this study on the generation of ROS, could
therefore have activated transcription via the CMV promoter. Further, the adaptation of the standard
protocol to the Eppendorf format required several changes in the cell manipulation (i.e., extended
storage on ice, centrifugation steps), which might also influence the cell physiology.
3.5. Transfection of Primary Human T Cells
Both the Eppendorf and the HCD protocol were subsequently applied in preliminary experiments
to the transfection of activated T cells from two different donors. The results are summarized in Table 6.
Table 6. Transfection in Eppendorf tubes and HCD transfection of human primary T cells.
Polymer Density







Donor 1 Donor 2
Eppendorf tubes a control - - 0.8/0.9 0.8/0.7
75.8/78.2 93.3/91.3
6 2.4 0.28 19.4/13.6 2.0/6.1
35.1/39.6 78.9/80.1
5 2.0 0.23 7.8/15 0.9/1.8
48.4/38.1 86.1/88.5
3.7/8.2 0.7/2.4
4 1.6 0.18 56.8/44.7 89.9/89.3
HCD b Control - - 0.5 0.8
68.9 87.6
3.2 14.8
3 60 3.1 37.5 65.3
a 0.2 × 106 cells per sample, N/P 10, transfection volume: 0.5 mL, incubation with polyplexes 90 min, data represent
the results of experimental replicates using the same polyplexes for the two donors. b 5 × 106 cells per sample,
N/P 10, transfection volume: 0.25 mL, incubation 4 h. Amount of activated T cells (CD3+/CD25+) at the time of
transfection: Donor 1, 86%; Donor 2, 98%. The cells were incubated for 48 h in LymphoGrow medium supplemented
with 11 ng mL−1 rhIL-2 post-transfection. Transfection efficiencies are displayed in bold and cell viabilities in italic.
Obviously, transfection efficiencies are much lower for the primary T cells. This was to be expected,
as the experiments with the Jurkat cells had shown that cells are highly sensitive to even small changes
in the transfection conditions. Further optimization of the protocols is obviously necessary, before it
can be applied to primary T cells. However, even in these highly preliminary experiments, transfection
efficiencies were consistently above the values for the controls, something which is not the case for
primary T cells transfected with l-PEI [11].
The experimental replicates generally show variations up to three-fold for the transfection
efficiency. The major differences between the experiments was that the polyplexes were prepared
in parallel whereas their addition to the cells was time delayed (15 min to 20 min), i.e., storage of
the cells (on ice during the Eppendorf tubes protocol) and incubation of the polyplexes (at room
temperature) was slightly longer in the second replicate. Whether these differences are responsible
for the higher transfection efficiencies observed is currently under investigation in our laboratory.
At any rate, some similarities to the Jurkat cell results can be observed. While a polymer density of
3 µg per 106 cells seems adequate in the HCD protocol, for the Eppendorf tubes protocol 6 µg seem
more suitable. Independently of the donor, for Eppendorf tubes but not for HCD transfections, the
higher the transfection efficiency is, the lower the viability tends to be. Similar trends were observed
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for Jurkat cells during the optimization experiments. Finally, cells from donor 1 performed well in
the Eppendorf tube, but not in the HCD protocol, while the opposite was the case for cells from
donor 2. Here, one should notice that the level of activation of the cells was slightly different for
both donors, Table 6. We cannot exclude that the level of activation of the T lymphocytes might be
responsible for the observed results. Beside the activation status of the T lymphocytes, cell density,
pDNA dose, supplementation of the post-transfection cultivation medium with cytokines have been
recently proposed as additional parameters that should be optimized during the development of
transfection protocols for human primary T cells [9].
4. Conclusions
It has been speculated that the inability of PEI to transfect blood cells such as T lymphocytes
might be partly related to uptake and intracellular trafficking. The polycationic transfection agent
PDMAEMA, is indeed more suitable to transfect the human leukemia T cells (Jurkat cells) chosen in this
study as model cells for primary T lymphocytes. This might be related to a different uptake mechanism
as speculated recently by our group [20]. However, in the standard transfection protocol, transfection
efficiencies >70% could only be achieved at severely reduced viabilities. Better results were obtained in
a high cell density (HCD) transfection protocol, where the transfection agent (PDMAEMA-nanostar) is
added directly to the cell/pDNA mixture and where transfection efficiencies >70% are easily combined
with viabilities >70%. Even better results (>80% transfected cells at >80% viability) were obtained in a
protocol where polyplexes were used to transfect the cells in an Eppendorf tube. Both protocols use
higher cell densities. This intensifies the interaction with the polyplexes and accelerates the transfection
kinetics, which inter alia allows lowering the amounts of polymer per 106 cells used and in consequence
the cytotoxicity of the process. Whereas the Eppendorf tube protocol could in future be used to
effectively transfect cells at small scale for research purposes, the HCD protocol has excellent scale
up potential and thus could eventually become the basis for medical applications of T cell therapies.
Both protocols were tested for the transfection of primary T cells from two different donors. In these
preliminary experiments, the obtained transfection efficiencies were lower than for the Jurkat cells,
but significantly better than with l-PEI. Moreover, the cells from the two donors showed distinct
differences in their reaction to the conditions of the protocols, which presents the starting point for
further optimizations currently under way in our laboratory.
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